U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT06894693) titled 'A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies' on March 18.
Brief Summary: This study is an open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic profile in the body after infusion of RS001 injection, and preliminary efficacy in subjects with CD19-positive relapsed/refractory B-cell malignancies (BCM).
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
B-cell Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukemia
Intervention:
BIOLOGICAL: RS001 injection
CD19-CAR-mbIL15-DNT Cells.
Recruitment St...